Federal regulators have added a genuinely new kind of weapon to the multiple myeloma arsenal. On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide, sold as Zenbexus, for adults with the blood cancer who have already been through at least one prior line of treatment. It is the first drug of its class to reach myeloma patients, and it works less like a conventional poison and more like a hijacking of the cell’s own recycling machinery.
How a cereblon-targeting pill dismantles myeloma cells
Multiple myeloma is a cancer of plasma cells, the antibody-producing cells that live in bone marrow. It remains incurable for the vast majority of patients, who typically cycle through remissions and relapses as the disease outmaneuvers one treatment after another. Each relapse tends to be harder to treat than the last, which is why oncologists have pushed for drugs that attack the cancer through fundamentally different routes.
Iberdomide belongs to a category called cereblon E3 ligase modulators, or CELMoDs. Rather than simply blocking a target, the drug latches onto a protein called cereblon and redirects it to tag two transcription factors, Ikaros and Aiolos, for destruction by the cell’s ubiquitin-proteasome system. Myeloma cells lean heavily on those two proteins to survive, so degrading them starves the cancer. The FDA describes the clearance as covering iberdomide in combination with daratumumab and hyaluronidase-fihj and dexamethasone, a three- and four-drug regimen built around that degradation mechanism.
What the EXCALIBER-RRMM trial measured
The approval rests on a large randomized study called EXCALIBER-RRMM, a two-stage, multicenter, open-label trial that enrolled 939 patients with relapsed or refractory disease who had received one or two prior lines of therapy. Investigators compared the iberdomide-based combination against a standard daratumumab, bortezomib and dexamethasone regimen. The main yardstick was minimal residual disease negativity paired with complete response, a stringent measure of how thoroughly treatment clears cancer cells detectable in the marrow.
In the primary population, the rate of MRD-negative complete response at any time reached 41 percent among patients taking the iberdomide combination, compared with 21 percent in the comparison arm. Because the clearance came through the accelerated pathway, that deep-response benchmark stands in for longer-term outcomes; the agency can require confirmatory evidence that the regimen ultimately extends or improves lives before the approval becomes permanent.
The trial’s design also defines the drug’s real-world boundaries. Patients whose disease was already refractory to a prior anti-CD38 antibody, or to prior bortezomib, were excluded, so the results speak to a specific population rather than to every relapsed case. The partner drugs follow their own schedules: daratumumab and hyaluronidase-fihj is given as a subcutaneous injection on a tapering calendar across each cycle, while dexamethasone is dosed weekly. That combination structure means the new pill is one component of a regimen, not a standalone therapy.
A boxed warning and a restricted distribution program
The prescribing information carries serious cautions. According to the agency’s oncology reviewers, iberdomide’s label includes a boxed warning for embryo-fetal toxicity and for serious venous and arterial blood clots, along with warnings for low white blood cell counts, infections and second cancers. Because of the risk to a developing fetus, the drug is available only through a restricted program called the Zenbexus Risk Evaluation and Mitigation Strategy. The recommended dose is 1 milligram taken by mouth once daily on days 1 through 21 of each 28-day cycle, continuing until the disease progresses or side effects become intolerable.
Those cautions shape how the regimen is likely to be used in practice. The clotting risk means many patients will need blood thinners or close monitoring, and the neutropenia and infection warnings put a premium on tracking blood counts between cycles. For a therapy taken as a daily oral pill over months or years, that ongoing surveillance is part of the treatment rather than an afterthought, and it factors into which patients are good candidates for the combination in the first place.
A new class arriving as older immunomodulators fade
The significance of the clearance goes beyond a single product. CELMoDs were engineered to keep working in cells that have grown resistant to older immunomodulatory drugs such as lenalidomide and pomalidomide, a resistance that eventually undermines many myeloma regimens. Oncology specialists have framed the decision as the first time the class has been folded into standard myeloma care, and one that lets physicians reach for the mechanism as early as a first relapse rather than holding it in reserve.
Targeted protein degradation, the broader strategy behind the drug, has been one of the most closely watched ideas in cancer research for the past decade. Instead of occupying a protein’s active site the way a traditional inhibitor does, degraders eliminate the protein outright, then move on to do it again. That catalytic quality is part of why researchers have hoped the approach could hold up against tumors that learn to shrug off conventional drugs. A working degrader in a common blood cancer offers an early, real-world test of whether that promise translates from the laboratory to the clinic.
The review moved through several of the agency’s expedited channels. It was conducted under Project Orbis, which allows international regulators to evaluate a cancer drug at the same time, with the FDA collaborating with Switzerland’s Swissmedic on this application. Iberdomide had already received breakthrough therapy and orphan drug designations and was granted priority review. Whether the deep responses seen in the trial translate into the long remissions patients hope for will depend on follow-up data, but the arrival of a working protein degrader marks a shift in how the disease can be attacked.
This article was produced with AI assistance and reviewed by the Morning Overview editorial team.
More from Morning Overview
